⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ARVN News
Arvinas, Inc
Catalyst Monitor: Q2 2026 Outlook Report - Trial Initiations, Completions, Top-line Results, Regulatory Filings, PDUFA Dates, and Expected Approvals
globenewswire.com
RPTX
ARVN
RGNX
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
globenewswire.com
ARVN
Form 8-K
sec.gov
ARVN
PFE
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
globenewswire.com
ARVN
PFE
Arevon Earns Gold Certification for Diversity, Equity, Inclusion, and Justice Initiatives from the Solar Energy Industries Association
prnewswire.com
ARVN
Form 8-K
sec.gov
ARVN
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
globenewswire.com
ARVN
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
globenewswire.com
ARVN
Form 8-K
sec.gov
ARVN
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
globenewswire.com
ARVN